



6 November 2017

ASX ANNOUNCEMENT

2018 Reimbursement Amounts Published by Center for Medicare and Medicaid Services (CMS)

Brisbane, Australia and Carlsbad, Calif.- ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status, is pleased to announce that CMS has published the new payment amounts for CPT code 93702, to take effect on 1 January 2018.

For 2018, the reimbursement amount for CPT code 93702 when billed by a hospital outpatient facility will increase to \$136, from \$127 in 2017, an increase of 7%. The physician reimbursement rate will remain unchanged at \$126.

**Richard Carreon
Managing Director & CEO**

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO

Morten Vigeland, ImpediMed CFO

T: +1 (760) 585-2100

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex[®] device. In addition, ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[™], sold in select markets globally.

For more information, visit www.impedimed.com.